ViAqua announces $4.3m investment to improve aquatic animal health

ViAqua Therapeutics announced Wednesday that it will invest $ 4.3 million to expand its platform to improve the health and nutrition of aquatic animals. The investments are led by S2G Ventures for its RNA-based aquaculture health platform. ViAqua is a biotechnology company founded to provide affordable ways to combat disease in aquaculture. Among the many investors the company has are the Technion Israel Institute of Technology, the company aims to create the first product to improve the health and nutrition of shrimp and other aquatic animals through the use of RNA while combating diseases common in shrimp. Diseases have created many problems in the shrimp industry for decades and there are very few treatment options. The problem with using RNA-based technology has been the high production costs in an aquatic environment. “Disease prevention is a major concern in the aquaculture sector and ViAqua has a promising technology platform to improve the health of shrimp and other species, “said Thiraphong Chansiri, President and CEO of Thai Union and one of ViAqua’s many investors in the venture. Lauren Mettler, Managing Director at S2G Ventures Oceans and Seafood said, “We are very excited to be working with this talented team and international group of co-investors who reflect the tremendous market opportunity.”

Comments are closed.